top of page
DSC_0107 (5).JPG

WAEL M. ELSHAMY, PH.D.

Associate Professor

Dr. ElShamy obtained his B.Sc. in Chemistry in 1986 from the Ayn-Shams University in Egypt, and his Ph.D. in Medical Biochemistry and Biophysics from the Royal Karolinska Institute in Sweden, in 1998. After completing a post-doctoral fellowship in Dana-Farber Cancer Institute and Harvard Medical School he became an instructor at Harvard Medical School. He was the Dr. Lawrence and Mrs. Bo Hing chan Tseu American Cancer Society Research Scholar from 2009 to 2013. Most recently, he was Director of the Molecular Cancer Therapeutic Program at the University of Mississippi Medical Center’s Cancer Institute. He joined MSMRC in 2017.

Wael ElShamy, Ph.D.: Inner_about

PUBLICATIONS

  1. Ryan D, Sinha A, Bogan D, Davies J, Koziol J, ElShamy W. A niche that triggers aggressiveness within BRCA1-IRIS overexpressing triple negative tumors is supported by reciprocal interactions with the microenvironment. Oncotarget. 2017 8:103182-103206. PDF

  2. Sinha A, Paul BT, Sullivan LM, Sims H, El Bastawisy A, Yousef HF, Zekri AN, Bahnassy AA, ElShamy WM. BRCA1-IRIS overexpression promotes and maintains the tumor initiating phenotype: implications for triple negative breast cancer early lesions. Oncotarget. 2017 Feb 7;8(6):10114-10135. PDF

  3. Ananthula S, Sinha A, El Gassim M, Batth S, Marshall GD Jr, Gardner LH, Shimizu Y, ElShamy WM. Geminin overexpression-dependent recruitment and crosstalk with mesenchymal stem cells enhance aggressiveness in triple negative breast cancers. Oncotarget. 2016 Apr 12;7(15):20869-89. PDF

  4. Blanchard Z, Paul BT, Craft B, ElShamy WM. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers. Breast Cancer Res. 2015 Jan 13;17:5. PDF

  5. Blanchard Z, Mullins N, Ellipeddi P, Lage JM, McKinney S, El-Etriby R, Zhang X, Isokpehi R, Hernandez B, Elshamy WM. Geminin overexpression promotes imatinib sensitive breast cancer: a novel treatment approach for aggressive breast cancers, including a subset of triple negative. PLoS One. 2014 Apr 30;9(4):e95663. PDF

  6. Gardner L, Malik R, Shimizu Y, Mullins N, ElShamy WM. Geminin overexpression prevents the completion of topoisomerase IIα chromosome decatenation, leading to aneuploidy in human mammary epithelial cells. Breast Cancer Res. 2011 May 19;13(3):R53. PDF

  7. All of Dr. Wael ElShamy’s Publications

Wael ElShamy, Ph.D.: About

WE NEED YOUR HELP

Our research programs are funded primarily by grants from the National Institutes of Health (NIH) and private donations. These help accelerate the progress of research through the purchase of laboratory supplies and equipment or the recruitment of additional laboratory personnel. Thank you!

Wael ElShamy, Ph.D.: Homepage_about
bottom of page